Soft Tissue Sarcomas

Chemotherapy Before Surgery Improves Treatment of Sarcoma (11-7-2016)

For patients with localized soft-tissue sarcoma of the trunk or extremities who are high risk for relapse, the use of anthracycline plus ifosfamide chemotherapy prior to surgery appears to improve survival. Chemotherapy administered before surgery is... Continue Reading

Halaven Approved for Liposarcoma (02-4-2016)

The United States Food and Drug Administration (FDA) has approved the chemotherapy agent Halaven (eribulin) for the treatment of liposarcoma. It’s the first drug approved for liposarcoma that has demonstrated an improvement in overall survival. Halaven... Continue Reading

Yondelis® Approved for Treatment of Soft Tissue Sarcoma (11-2-2015)

The United States Food and Drug Administration (FDA) approved the chemotherapy agent, Yondelis® (trabectedin), for the treatment of liposarcoma and leiomyosarcoma—two types of soft-tissue sarcomas.1 The approval of Yondelis is for patients whose cancer... Continue Reading

Yondelis® Bests Standard Therapy in Liposarcoma and Leiomyosarcoma (10-20-2015)

The chemotherapy agent, Yondelis® (trabectedine), improves outcomes compared to the standard agent, DTIC (dacarbazine), in patients with advanced liposarcoma or leiomyosarcoma that has recurred or progressed following prior therapies. These results were... Continue Reading

Longer Overall Survival for Patients with Soft Tissue Sarcoma Treated with Halaven® (06-11-2015)

Halaven® (eribulin) may extend overall survival in patients with previously treated, advanced soft tissue sarcoma (STS). These findings were presented at 2015 Annual Meeting of the American Society of Clinical Oncology (May 29–June 2, Chicago, Illinois)... Continue Reading

YONDELIS® (trabectedin) for the Treatment of Patients with Advanced Soft Tissue Sarcoma (02-4-2015)

The U.S. Food and Drug Administration (FDA) has granted Priority Review for the New Drug Application (NDA) for YONDELIS® (trabectedin) to treat patients with advanced soft tissue sarcoma (STS), including liposarcoma and leiomyosarcoma subtypes. YONDELIS®... Continue Reading

Torisel Improves Event-Free Survival in Rhabdomyosarcoma Patients (06-27-2014)

In a study presented at the 2014 American Society of Clinical Oncology® meeting in Chicago, researchers reported that Torisel® (temsirolimus) added to a chemotherapy regimen improved event-free survival in young patients with rhabdomyosarcoma. Rhabdomyosarcoma... Continue Reading

Regorafenib May Expand GIST Treatment Options (06-13-2012)

Among patients with gastrointestinal stromal tumors (GIST) that worsen in spite of standard treatment, the investigational drug regorafenib delays cancer progression. These results—from a Phase III clinical trial—were presented at the 2012 Annual... Continue Reading